Clinical trials
IgAN clinical trials
Below are recruiting igan clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06935357RecruitingPhase 3
Felzartamab infusions for IgA nephropathy
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Little Rock, ArkansasAges 18 years+ - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT06989359RecruitingPhase 2
Study of ADX-038 for complement-related kidney disease
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Doral, FloridaAges 18 years+ - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70 - NCT06676579RecruitingPhase 2
Avacopan for active IgA kidney disease with crescents
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Jacksonville, FloridaAges 18 years+ - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Aurora, ColoradoAges 2–18 - NCT07390123RecruitingPhase 3
Study of HSK39297 for IgA Nephropathy (IgAN)
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Huangshan City, AnhuiAges 18 years+ - NCT07146906RecruitingPhase 2
Study of zigakibart for IgA nephropathy
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
Denver, ColoradoAges 18–100 - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Woolloongabba, QueenslandAges 18 years+ - NCT05234463Recruiting
Study links complement activity to IgA kidney disease severity
This study looks at how parts of the immune system (called complement) may relate to how severe IgA kidney disease is. It may help doctors understand disease activity better, even if the study is mainly observational.
StrasbourgAges 18 years+ - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+ - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Birmingham, AlabamaAges 18–99 - NCT07522099RecruitingPhase 2
Study of ADARx Treatment for Kidney Disease in Chinese Adults
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Shenzhen, GuangdongAges 18 years+ - NCT06676007Recruiting
Early use of a targeted budesonide for IgA nephropathy
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Chengdu, SichuanAges 18–75 - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06819826RecruitingPhase 3
Study of SC0062 for IgA Nephropathy with Proteinuria
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
Guangzhou, Yuexiu DistrictAges 18 years+ - NCT06926244Recruiting
Studying resistance to IgA nephropathy treatments in real life
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
ParisAges 18 years+ - NCT06952426Recruiting
IgA Nephropathy app study for patients and caregivers
This study uses a mobile app to track how IgA nephropathy (IgAN) affects daily life and what treatments people use. It’s open to patients and their caregivers to help researchers learn more about the disease.
Boston, MassachusettsAges 18 years+ - NCT06983028RecruitingPhase 2
Testing atacicept for multiple kidney diseases
This trial tests a medicine called atacicept in adults and children with several types of kidney disease. The goal is to see if it can reduce protein in the urine and help protect kidney function.
Brisbane, CaliforniaAges 2 years+ - NCT07056595Recruiting
Finerenone for IgA nephropathy patients
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
MoscowAges 18 years+ - NCT07295808Recruiting
Study of IgA antibodies in kidney disease
This study looks at a specific type of antibody called IgA in patients with certain kidney diseases. It aims to understand which IgA antibodies cause kidney damage, which could help develop better treatments.
LimogesAges 18 years+
Hear when a new IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for igan?
- Yes. Clin2 currently lists 32 recruiting igan studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a igan trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a igan trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.